SOC Telemed to Participate in Upcoming Investor Conference
News provided by
Share this article
Share this article
RESTON, Va., May 17, 2021 /PRNewswire/ SOC Telemed, Inc. ( SOC ), the largest national provider of acute care telemedicine, today announced that John Kalix, Chief Executive Officer, and Chris Knibb, Chief Financial Officer, will participate in the 2021 RBC Capital Markets Global Healthcare Conference, including a fireside chat on Tuesday, May 18, 2021 at 4:15pm ET. A webcast link and related presentation materials will be available at https://investors.soctelemed.com/.
About SOC Telemed
SOC Telemed (SOC) is the leading national provider of acute telemedicine technology and solutions to hospitals, health systems, post-acute providers, physician networks, and value-based care organizations since 2004. Built on proven and scalable infrastructure as an enterprise-wide solution, SOC s technology platform, Telemed IQ, rapidly deploys and seamlessly optimizes telemedici
Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update
News provided by
Share this article
Share this article
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update. We continue to work closely with our existing clinical trial sites, as well as add new sites, to address the impact that the COVID-19 pandemic has had on patient enrollment in the pivotal Phase 3 RAPID trial of etripamil in patients with PSVT. While we are encouraged by recent improvements in enrollment rates, we now expect to report topline data from the RAPID trial in the second half of 2022, said Joseph Oliveto, President and Chief Executiv
Share this article
Share this article
LONDON, May 17, 2021 /PRNewswire/ Governments urgently need to limit speeds to 30 km/h (20 mph) on streets where people walk, live and play, says a new call to action from leading global agencies, NGOs and policymakers as part of COVID-19 response and recovery during the Streets For Life campaign for UN Global Road Safety Week (17 - 23 May) and beyond.
A special World Health Organization (WHO) press conference was held by Dr Tedros Adhanom Ghebreyesus, WHO Director-General, and Zoleka Mandela, Global Ambassador, Child Health Initiative.
The Streets for Life campaign highlights the benefits of low-speed streets in urban areas to reduce road traffic injury - responsible for 1.35 million deaths each year and the leading global killer of young people – and deliver co-benefits through a shift to walking and cycling, delivering improved air quality, climate action and equity which are essential for building back from Covid-19.
/PRNewswire/ Paragon 28, Inc. a market leading orthopedic medical device company focused exclusively on the foot and ankle, today announced that the Company.
Share this article
Share this article
ALBANY, N.Y., May 17, 2021 /PRNewswire/ Growing sources of enzymes and ceaseless advances in the processing technologies continue to open breakthroughs in biotechnology. Strides by medical enzyme technology market have opened new avenues in human disease diagnosis and treatment. The technology itself has made striking leaps on back of industry players harnessing the various tools most notably recombinant DNA technology and protein engineering to meet emerging demands. These tools have enabled medical researchers to modify enzymes and add to the repository of knowledge of medical-grade enzymes. Interesting cases in point are preserving the thermo stability after immobilization and improving the stability of the promising category of medical enzymes, all of which point to the vast revenue potential in the medical enzyme technology market.